Dr Joanne Mountford

  • Honorary Associate Professor (School of Cardiovascular & Metabolic Health)

email: Jo.Mountford@glasgow.ac.uk

R332A Level 3, Davidson Building, Glasgow G12 8QQ

Research interests

Member: Vascular Research

Research: Development of stem cell based technologies and regenerative medicines

 

Publications

List by: Type | Date

Jump to: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003
Number of items: 43.

2021

Bozhilov, Y. K., Downes, D. J., Telenius, J., Marieke Oudelaar, A., Olivier, E. N., Mountford, J. C., Hughes, J. R., Gibbons, R. J. and Higgs, D. R. (2021) A gain-of-function single nucleotide variant creates a new promoter which acts as an orientation-dependent enhancer-blocker. Nature Communications, 12, 3806. (doi: 10.1038/s41467-021-23980-6) (PMID:34155213) (PMCID:PMC8217497)

2020

Thirlwell, K. L. et al. (2020) Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditions. Cytotherapy, 22(12), pp. 762-771. (doi: 10.1016/j.jcyt.2020.07.010) (PMID:32828673)

2019

Mountford, J. C. and Connelly, K. A. (2019) Stem cell biology and the cardiovascular system. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 31-44. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_4)

2018

MacAskill, M. G. et al. (2018) Robust revascularization in models of limb ischemia using a clinically translatable human stem cell-derived endothelial cell product. Molecular Therapy, 26(7), pp. 1669-1684. (doi: 10.1016/j.ymthe.2018.03.017) (PMID:29703701) (PMCID:PMC6035339)

2017

Yang, C.-T., Ma, R., Axton, R. A., Jackson, M., Taylor, A. H., Fidanza, A., Marenah, L., Frayne, J., Mountford, J. C. and Forrester, L. M. (2017) Activation of KLF1 Enhances the differentiation and maturation of red blood cells from human pluripotent stem cells. Stem Cells, 35(4), pp. 886-897. (doi: 10.1002/stem.2562) (PMID:28026072) (PMCID:PMC5396323)

MacAskill, M. G., Tavares, A. S., Wu, J., Lucatelli, C., Mountford, J. C., Baker, A. H., Newby, D. and Hadoke, P. W.F. (2017) PET cell tracking using (18)F-FLT is not limited by local reuptake of free radiotracer. Scientific Reports, 7, 44233. (doi: 10.1038/srep44233) (PMID:28287126) (PMCID:PMC5347009)

2016

Olivier, E. N., Marenah, L., McCahill, A., Condie, A., Cowan, S. and Mountford, J. C. (2016) High efficiency serum free feeder free erythroid differentiation of human pluripotent stem cells using small molecules. Stem Cells Translational Medicine, 5(10), pp. 1394-1405. (doi: 10.5966/sctm.2015-0371) (PMID:27400796) (PMCID:PMC5031182)

Jackson, M. et al. (2016) Enforced expression of HOXB4 in human embryonic stem cells enhances the production of hematopoietic progenitors but has no effect on the maturation of red blood cells. Stem Cells Translational Medicine, 5(8), pp. 981-990. (doi: 10.5966/sctm.2015-0324) (PMID:27352929)

Alhasan, A. A. et al. (2016) Circular RNA enrichment in platelets is a signature of transcriptome degradation. Blood, 127(9), e1-e11. (doi: 10.1182/blood-2015-06-649434) (PMID:26660425)

Boulberdaa, M. et al. (2016) A role for the long non-coding RNA SENCR in commitment and function of endothelial cells. Molecular Therapy, 24(5), pp. 978-990. (doi: 10.1038/mt.2016.41) (PMID:26898221) (PMCID:PMC4876031)

2015

Garate, Z. et al. (2015) Generation of high number of healthy erythroid cells from gene-edited pyruvate kinase deficiency patient-specific induced pluripotent stem cells. Stem Cell Reports, 5(6), pp. 1053-1066. (doi: 10.1016/j.stemcr.2015.10.002) (PMID:26549847) (PMCID:PMC4682065)

Mittra, J., Tait, J., Mastroeni, M., Turner, M.L., Mountford, J.C. and Bruce, K. (2015) Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells. New Biotechnology, 32(1), pp. 180-190. (doi: 10.1016/j.nbt.2014.07.008)

2013

Scott, E., Loya, K., Mountford, J., Milligan, G. and Baker, A. H. (2013) MicroRNA regulation of endothelial homeostasis and commitment—implications for vascular regeneration strategies using stem cell therapies. Free Radical Biology and Medicine, 64, pp. 52-60. (doi: 10.1016/j.freeradbiomed.2013.04.037)

Lindsay, S.L. , Johnstone, S.A., Mountford, J.C., Sheikh, S., Allan, D.B., Clark, L. and Barnett, S.C. (2013) Human mesenchymal stem cells isolated from olfactory biopsies but not bone enhance CNS myelinationin vitro. Glia, 61(3), pp. 368-382. (doi: 10.1002/glia.22440)

2012

Kaupisch, A., Kennedy, L., Stelmanis, V., Tye, B., Kane, N.M., Mountford, J.C., Courtney, A. and Baker, A.H. (2012) Derivation of vascular endothelial cells from human embryonic stem cells under GMP-compliant conditions: towards clinical studies in ischaemic disease. Journal of Cardiovascular Translational Research, 5(5), pp. 605-617. (doi: 10.1007/s12265-012-9379-2)

Marenah, L., Allan, E.K., Mountford, J.C., Holyoake, T.L., Jorgensen, H.G. and Elliott, M.A. (2012) Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography, 26(5), pp. 545-547. (doi: 10.1002/bmc.1686)

Kane, N. M. et al. (2012) Role of MicroRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells, 30(4), pp. 643-654. (doi: 10.1002/stem.1026)

Terrin, A. et al. (2012) PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome. Journal of Cell Biology, 198(4), pp. 607-621. (doi: 10.1083/jcb.201201059)

2011

Mountford, J. C. and Turner, M. (2011) In vitro production of red blood cells. Transfusion and Apheresis Science, 45(1), pp. 85-89. (doi: 10.1016/j.transci.2011.06.007) (PMID:21723197)

Yung, S. et al. (2011) Large-scale transcriptional profiling and functional assays reveal important roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human embryonic stem cells. Human Molecular Genetics, 20(24), pp. 4932-4946. (doi: 10.1093/hmg/ddr431)

2010

Burton, P. et al. (2010) Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochemical Journal, 432(3), pp. 575-584. (doi: 10.1042/BJ20100726)

Kane, N. M. et al. (2010) Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. Molecular Therapy, 18(12), pp. 2139-2145. (doi: 10.1038/mt.2010.231)

Burton, P. et al. (2010) Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 38(4), pp. 1058-1061. (doi: 10.1042/BST0381058)

Kane, N. M., Meloni, M., Spencer, H. L., Craig, M. A., Strehl, R., Milligan, G., Houslay, M. D., Mountford, J. C., Emanueli, C. and Baker, A. H. (2010) Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(7), pp. 1389-1397. (doi: 10.1161/ATVBAHA.110.204800)

Mountford, J.C., Olivier, E. and Turner, M. (2010) Prospects for the manufacture of red cells for transfusion. British Journal of Haematology, 149(1), pp. 22-34. (doi: 10.1111/j.1365-2141.2010.08079.x)

Andrews, P. et al. (2010) High content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. Biochemical Journal, 432(Pt 1), pp. 21-33. (doi: 10.1042/BJ20101022)

Burton, P. et al. (2010) Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 38(4), pp. 1058-1061. (doi: 10.1042/BST0381058)

Mountford, J.C., Olivier, E., Jordanides, N. E., de Sousa, P. and Turner, M. L. (2010) Red blood cells from pluripotent stem cells for use in transfusion. Regenerative Medicine, 5(3), pp. 411-423. (doi: 10.2217/rme.10.22)

2009

Pellicano, F., Copland, M. , Jorgensen, H. G. , Mountford, J., Leber, B. and Holyoake, T. L. (2009) BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cβ. Blood, 114(19), pp. 4186-4196. (doi: 10.1182/blood-2009-05-219550)

Davies, A. et al. (2009) Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 23(11), pp. 1999-2006. (doi: 10.1038/leu.2009.166)

Hatziieremia, S., Jordanides, N.E., Holyoake, T.L., Mountford, J.C. and Jorgensen, H.G. (2009) Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Experimental Hematology, 37(6), pp. 692-700. (doi: 10.1016/j.exphem.2009.02.006)

Myssina, S. et al. (2009) Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 37(2), pp. 206-214. (doi: 10.1016/j.exphem.2008.10.013)

Khanim, F.L. et al. (2009) Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS ONE, 4(12), e8147. (doi: 10.1371/journal.pone.0008147)

2008

Mountford, J.C. (2008) Human embryonic stem cells: origins, characteristics and potential for regenerative therapy. Transfusion Medicine, 18(1), pp. 1-12. (doi: 10.1111/j.1365-3148.2007.00807.x)

2007

Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research, 13(17), pp. 5048-5055. (doi: 10.1158/1078-0432.CCR-07-0919)

Allan, E.K., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G. and Mountford, J.C. (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 109(9), pp. 4016-4019. (doi: 10.1182/blood-2006-11-057521)

2006

Holyoake, T.L., Jordanides, N., Jorgensen, H.G. and Mountford, J.C. (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood, 108(4), pp. 1370-1373. (doi: 10.1182/blood-2006-02-003145)

Copland, M., Hamilton, A., Eirick, L., Baird, J., Allan, E., Jordanides, N., Barow, M., Mountford, J. and Holyoake, T. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107(11), pp. 4532-4539. (doi: 10.1182/blood-2005-07-2947)

2005

Jorgensen, H.G. , Allan, E.K., Mountford, J.C., Richmond, L., Harrison, S., Elliott, M.A. and Holyoake, T.L. (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33(10), pp. 1140-1146. (doi: 10.1016/j.exphem.2005.05.020)

Allan, E.K., Eaves, C.J., Elliott, M.A., Godden, J.L., Graham, S.M., Holyoake, T.L., Jorgensen, H.G. , Mountford, J.C. and Richmond, L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19(7), pp. 1184-1191. (doi: 10.1038/sj.leu.2403785)

Elrick, L.J., Holyoake, T.L., Jorgensen, H.G. and Mountford, J.C. (2005) Punish the parent not the progeny. Blood, 105(5), pp. 1862-1866. (doi: 10.1182/blood-2004-08-3373)

Bunce, C., Hayden, R., Mountford, J. and Vanin, E. (2005) All-trans retinoic acid increases transgene expression in MSCV-transduced cells, via a mechanism that is retinoid receptor dependent but independent of cellular differentiation. Human Gene Therapy, 16, pp. 132-138.

2003

Clark, A.D., Jorgensen, H.G. , Mountford, J.C. and Holyoake, T.L. (2003) Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology, 41(2-3), pp. 111-131. (doi: 10.1023/A:1024822722285)

This list was generated on Sun Oct 2 12:28:45 2022 BST.
Jump to: Articles | Book Sections
Number of items: 43.

Articles

Bozhilov, Y. K., Downes, D. J., Telenius, J., Marieke Oudelaar, A., Olivier, E. N., Mountford, J. C., Hughes, J. R., Gibbons, R. J. and Higgs, D. R. (2021) A gain-of-function single nucleotide variant creates a new promoter which acts as an orientation-dependent enhancer-blocker. Nature Communications, 12, 3806. (doi: 10.1038/s41467-021-23980-6) (PMID:34155213) (PMCID:PMC8217497)

Thirlwell, K. L. et al. (2020) Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditions. Cytotherapy, 22(12), pp. 762-771. (doi: 10.1016/j.jcyt.2020.07.010) (PMID:32828673)

MacAskill, M. G. et al. (2018) Robust revascularization in models of limb ischemia using a clinically translatable human stem cell-derived endothelial cell product. Molecular Therapy, 26(7), pp. 1669-1684. (doi: 10.1016/j.ymthe.2018.03.017) (PMID:29703701) (PMCID:PMC6035339)

Yang, C.-T., Ma, R., Axton, R. A., Jackson, M., Taylor, A. H., Fidanza, A., Marenah, L., Frayne, J., Mountford, J. C. and Forrester, L. M. (2017) Activation of KLF1 Enhances the differentiation and maturation of red blood cells from human pluripotent stem cells. Stem Cells, 35(4), pp. 886-897. (doi: 10.1002/stem.2562) (PMID:28026072) (PMCID:PMC5396323)

MacAskill, M. G., Tavares, A. S., Wu, J., Lucatelli, C., Mountford, J. C., Baker, A. H., Newby, D. and Hadoke, P. W.F. (2017) PET cell tracking using (18)F-FLT is not limited by local reuptake of free radiotracer. Scientific Reports, 7, 44233. (doi: 10.1038/srep44233) (PMID:28287126) (PMCID:PMC5347009)

Olivier, E. N., Marenah, L., McCahill, A., Condie, A., Cowan, S. and Mountford, J. C. (2016) High efficiency serum free feeder free erythroid differentiation of human pluripotent stem cells using small molecules. Stem Cells Translational Medicine, 5(10), pp. 1394-1405. (doi: 10.5966/sctm.2015-0371) (PMID:27400796) (PMCID:PMC5031182)

Jackson, M. et al. (2016) Enforced expression of HOXB4 in human embryonic stem cells enhances the production of hematopoietic progenitors but has no effect on the maturation of red blood cells. Stem Cells Translational Medicine, 5(8), pp. 981-990. (doi: 10.5966/sctm.2015-0324) (PMID:27352929)

Alhasan, A. A. et al. (2016) Circular RNA enrichment in platelets is a signature of transcriptome degradation. Blood, 127(9), e1-e11. (doi: 10.1182/blood-2015-06-649434) (PMID:26660425)

Boulberdaa, M. et al. (2016) A role for the long non-coding RNA SENCR in commitment and function of endothelial cells. Molecular Therapy, 24(5), pp. 978-990. (doi: 10.1038/mt.2016.41) (PMID:26898221) (PMCID:PMC4876031)

Garate, Z. et al. (2015) Generation of high number of healthy erythroid cells from gene-edited pyruvate kinase deficiency patient-specific induced pluripotent stem cells. Stem Cell Reports, 5(6), pp. 1053-1066. (doi: 10.1016/j.stemcr.2015.10.002) (PMID:26549847) (PMCID:PMC4682065)

Mittra, J., Tait, J., Mastroeni, M., Turner, M.L., Mountford, J.C. and Bruce, K. (2015) Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells. New Biotechnology, 32(1), pp. 180-190. (doi: 10.1016/j.nbt.2014.07.008)

Scott, E., Loya, K., Mountford, J., Milligan, G. and Baker, A. H. (2013) MicroRNA regulation of endothelial homeostasis and commitment—implications for vascular regeneration strategies using stem cell therapies. Free Radical Biology and Medicine, 64, pp. 52-60. (doi: 10.1016/j.freeradbiomed.2013.04.037)

Lindsay, S.L. , Johnstone, S.A., Mountford, J.C., Sheikh, S., Allan, D.B., Clark, L. and Barnett, S.C. (2013) Human mesenchymal stem cells isolated from olfactory biopsies but not bone enhance CNS myelinationin vitro. Glia, 61(3), pp. 368-382. (doi: 10.1002/glia.22440)

Kaupisch, A., Kennedy, L., Stelmanis, V., Tye, B., Kane, N.M., Mountford, J.C., Courtney, A. and Baker, A.H. (2012) Derivation of vascular endothelial cells from human embryonic stem cells under GMP-compliant conditions: towards clinical studies in ischaemic disease. Journal of Cardiovascular Translational Research, 5(5), pp. 605-617. (doi: 10.1007/s12265-012-9379-2)

Marenah, L., Allan, E.K., Mountford, J.C., Holyoake, T.L., Jorgensen, H.G. and Elliott, M.A. (2012) Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography, 26(5), pp. 545-547. (doi: 10.1002/bmc.1686)

Kane, N. M. et al. (2012) Role of MicroRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells, 30(4), pp. 643-654. (doi: 10.1002/stem.1026)

Terrin, A. et al. (2012) PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome. Journal of Cell Biology, 198(4), pp. 607-621. (doi: 10.1083/jcb.201201059)

Mountford, J. C. and Turner, M. (2011) In vitro production of red blood cells. Transfusion and Apheresis Science, 45(1), pp. 85-89. (doi: 10.1016/j.transci.2011.06.007) (PMID:21723197)

Yung, S. et al. (2011) Large-scale transcriptional profiling and functional assays reveal important roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human embryonic stem cells. Human Molecular Genetics, 20(24), pp. 4932-4946. (doi: 10.1093/hmg/ddr431)

Burton, P. et al. (2010) Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochemical Journal, 432(3), pp. 575-584. (doi: 10.1042/BJ20100726)

Kane, N. M. et al. (2010) Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. Molecular Therapy, 18(12), pp. 2139-2145. (doi: 10.1038/mt.2010.231)

Burton, P. et al. (2010) Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 38(4), pp. 1058-1061. (doi: 10.1042/BST0381058)

Kane, N. M., Meloni, M., Spencer, H. L., Craig, M. A., Strehl, R., Milligan, G., Houslay, M. D., Mountford, J. C., Emanueli, C. and Baker, A. H. (2010) Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(7), pp. 1389-1397. (doi: 10.1161/ATVBAHA.110.204800)

Mountford, J.C., Olivier, E. and Turner, M. (2010) Prospects for the manufacture of red cells for transfusion. British Journal of Haematology, 149(1), pp. 22-34. (doi: 10.1111/j.1365-2141.2010.08079.x)

Andrews, P. et al. (2010) High content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. Biochemical Journal, 432(Pt 1), pp. 21-33. (doi: 10.1042/BJ20101022)

Burton, P. et al. (2010) Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 38(4), pp. 1058-1061. (doi: 10.1042/BST0381058)

Mountford, J.C., Olivier, E., Jordanides, N. E., de Sousa, P. and Turner, M. L. (2010) Red blood cells from pluripotent stem cells for use in transfusion. Regenerative Medicine, 5(3), pp. 411-423. (doi: 10.2217/rme.10.22)

Pellicano, F., Copland, M. , Jorgensen, H. G. , Mountford, J., Leber, B. and Holyoake, T. L. (2009) BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cβ. Blood, 114(19), pp. 4186-4196. (doi: 10.1182/blood-2009-05-219550)

Davies, A. et al. (2009) Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 23(11), pp. 1999-2006. (doi: 10.1038/leu.2009.166)

Hatziieremia, S., Jordanides, N.E., Holyoake, T.L., Mountford, J.C. and Jorgensen, H.G. (2009) Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Experimental Hematology, 37(6), pp. 692-700. (doi: 10.1016/j.exphem.2009.02.006)

Myssina, S. et al. (2009) Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 37(2), pp. 206-214. (doi: 10.1016/j.exphem.2008.10.013)

Khanim, F.L. et al. (2009) Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS ONE, 4(12), e8147. (doi: 10.1371/journal.pone.0008147)

Mountford, J.C. (2008) Human embryonic stem cells: origins, characteristics and potential for regenerative therapy. Transfusion Medicine, 18(1), pp. 1-12. (doi: 10.1111/j.1365-3148.2007.00807.x)

Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research, 13(17), pp. 5048-5055. (doi: 10.1158/1078-0432.CCR-07-0919)

Allan, E.K., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G. and Mountford, J.C. (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 109(9), pp. 4016-4019. (doi: 10.1182/blood-2006-11-057521)

Holyoake, T.L., Jordanides, N., Jorgensen, H.G. and Mountford, J.C. (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood, 108(4), pp. 1370-1373. (doi: 10.1182/blood-2006-02-003145)

Copland, M., Hamilton, A., Eirick, L., Baird, J., Allan, E., Jordanides, N., Barow, M., Mountford, J. and Holyoake, T. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107(11), pp. 4532-4539. (doi: 10.1182/blood-2005-07-2947)

Jorgensen, H.G. , Allan, E.K., Mountford, J.C., Richmond, L., Harrison, S., Elliott, M.A. and Holyoake, T.L. (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33(10), pp. 1140-1146. (doi: 10.1016/j.exphem.2005.05.020)

Allan, E.K., Eaves, C.J., Elliott, M.A., Godden, J.L., Graham, S.M., Holyoake, T.L., Jorgensen, H.G. , Mountford, J.C. and Richmond, L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19(7), pp. 1184-1191. (doi: 10.1038/sj.leu.2403785)

Elrick, L.J., Holyoake, T.L., Jorgensen, H.G. and Mountford, J.C. (2005) Punish the parent not the progeny. Blood, 105(5), pp. 1862-1866. (doi: 10.1182/blood-2004-08-3373)

Bunce, C., Hayden, R., Mountford, J. and Vanin, E. (2005) All-trans retinoic acid increases transgene expression in MSCV-transduced cells, via a mechanism that is retinoid receptor dependent but independent of cellular differentiation. Human Gene Therapy, 16, pp. 132-138.

Clark, A.D., Jorgensen, H.G. , Mountford, J.C. and Holyoake, T.L. (2003) Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology, 41(2-3), pp. 111-131. (doi: 10.1023/A:1024822722285)

Book Sections

Mountford, J. C. and Connelly, K. A. (2019) Stem cell biology and the cardiovascular system. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 31-44. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_4)

This list was generated on Sun Oct 2 12:28:45 2022 BST.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Materials exploitation of the biointerface to control MSC quality and niche phenotype
    Biotechnology and Biological Sciences Research Council
    2017 - 2019
     
  • Engineering growth factor microenvironments- a new therapeutic paradigm for regenerative medicine
    Engineering and Physical Sciences Research Council
    2016 - 2021
     
  • BHF Pump Priming Grant: How does the landscape of long non-coding RNA impact upon endothelial differentiation and specification from hES cells?
    British Heart Foundation
    2014 - 2015
     
  • Defining miRNA signatures that regulate pericyte proliferation: a novel approach to develop miRNA-based therapeutic strategies for the treatment of ischaemic complications.
    British Heart Foundation
    2014 - 2016
     
  • Red Blood Cell Project
    Scottish National Blood Transfusion Service
    2014 - 2017
     
  • BHF Centre for regenerative medicine
    British Heart Foundation
    2014 - 2017
     
  • BloodPharma 2
    Wellcome Trust
    2013 - 2017
     
  • Scalable in Vitro Production of Red Cells for Clinical Transfusion
    Wellcome Trust
    2013 - 2017
     
  • Red blood cell programme
    Scottish Enterprise
    2013 - 2016
     
  • TRANSLATING HUMAN EMBRYONIC STEM CELL-DERIVED ENDOTHELIAL CELL THERAPY TO THE CLINIC
    Medical Research Council
    2013 - 2016
     
  • Characterisation of T16, a novel stem cell survival compound (ISSF Catalyst Fund)
    Wellcome Trust
    2011 - 2014
     
  • Red blood cell programme
    Scottish Funding Council
    2011 - 2016
     
  • In vitro and in vivo analysis of stem cell commitment to vascular endothelial cells
    British Heart Foundation
    2011 - 2015
     
  • Clinical translation of endothelial cells derived from human embryonic stem cells
    Innovate UK
    2010 - 2011
     
  • Production of cardiomyocytes from human embryonic stem cells
    Stem Cells for Safer Medicines
    2009 - 2010
     
  • Proof of principle: Human embryonic stem cell derived red cell concentrates for clinical transfusion
    Wellcome Trust
    2009 - 2013
     
  • Effect of major efflux transporters on the intracellular concentration of dasatinib in CML CD34+ patient cells and cell lines
    Tenovus Scotland
    2009 - 2009
     
  • Measurement and modulation of tyrosine kinase inhibitor drug levels in chronic myeloid leukaemia.
    Scottish Executive Health Department
    2007 - 2008
     
  • Generation of Cardiomyocytes from Mesenchymal Stem Cells derived from Adult Human Bone Marrow
    British Heart Foundation
    2005 - 2007
     
  • Do transporter proteins contribute to clinical resistance to imatinib in chronic myeloid leukaemia? A combined study in Liverpool and Glasgow, correlating transporter expression and function with Imatinib uptake and efflux.
    Leukaemia Research Fund
    2004 - 2007
     
  • Novel drug combinations for eradication of Ph+/Bcr-Abl+ haemopoietic stem cells in chronic myeloid leukaemia (CML)
    Leukaemia Research Trust for Scotland
    2003 - 2006
     
  • Novel drug combinations for eradication of Ph+/Bcr-Abl+ haemopoietic stem cells in chronic myeloid leukaemia (CML)
    Medical Research Council
    2003 - 2006
     
  • Collection of normal cord blood cells as control samples. (a) Development of new treatment regimes for leukaemia: specificity of drug ef
    Medical Research Council
    2003 - 2006
     
  • Collection of normal cord blood cells as control samples. (b) Characterisation and expansion of haemopoietic stem cells from umbilical cor.
    Scottish National Blood Transfusion Service
    2003 - 2006
     

Additional information

Grant Advisory Board

  • 2006 - present: Scottish Stem Cell Network - Advisory Board Member

Invited International Presentations

  • 2008: Heriot-Watt University, Edinburgh, Scotland, UK - Invited Speaker: British Association for Gene Therapy, Public Open Day, Journeys in the Genetic Jungle.
  • 2008: Heriot-Watt University, Edinburgh, Scotland, UK - Invited Speaker: UK Nation Stem Cell Network Annual Meeting
  • 2007: Imperial College, London, UK - Invited Speaker: Drug Resistance Annual Workshop
  • 2007: Dundee, Scotland, UK - Chair: BBSRC Public Debate. Stem Cell Science - 'Hope not Hype.'
  • 2007: Giens, France - Plenary Speaker: Club Hématopoïèse et Oncogenèse (CHO) Stem Cells and Cancer Meeting
  • 2007: Singapore - Plenary Speaker: AACR Centennial Conference. Translational Cancer Medicine: Technologies to Therapy
  • 2006: Erasmus University, Rotterdam, Netherlands - Invited Speaker: Basic and Translational Oncology 2006
  • 2006: Imperial College, London, UK - Invited Speaker: Dept of Haematology
  • 2005: Glasgow, Scotland, UK - Session Chair: Mesenchymal Stem Cell Biology. ISEH
  • 2005: Fettes College, Edinburgh, Scotland, UK - Invited Speaker: StemCell2005 Conference Schools Event
  • 2005: Birkbeck College, London, UK - Invited Speaker: EuroSciCon, Growth, Expansion and Differentiation of Stem Cells
  • 2005: Glasgow, Scotland, UK - Invited Speaker: Novartis Satellite Symposium, Leading the way in CML. ISEH,
  • 2004: Canada - Invited Participant: Leukemia & Lymphoma Society Special Workshop on Cancer Stem Cells (Closed meeting).
  • 2004: ASH San Diego, USA - Oral Presentation: Simultaneous Session, Abstr 716, Functional ABCG2 Is Expressed on CML Stem Cells and Its Inhibition Selectively Depletes CML CD34+ Cells.
  • 2004: Cyprus - Session Chair: BACR Workshop on Cancer Stem Cells and Telomerase.

Professional Learned Society

  • 2006 - present: International Society for Stem Cell Research - Member
  • 2005 - present: American Society of Hematology - Full International Member
  • 2005 - present: European Hematology Association - Member
  • 2005 - present: British Society for Hematology - Member

Research Fellowship

  • 2001 - 2002: Lemuel W Diggs Fellow in Experimental Hematology
  • 1997 - 2001: Barling-Radcliffe Prize Research Fellow